Actively Recruiting
PET Imaging Using FDG and FDHT Radiotracers to Detect Progressive Prostate and Salivary Gland Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-09-11
300
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying progressive prostate and salivary gland cancers to evaluate whether PET scans using two radiotracers, FDG and FDHT, can better detect cancer spread in the body. Preliminary studies showed FDG-PET scans can identify abnormal tumor metabolism and track treatment response through PSA changes. This study extends these methods by including FDHT, which targets androgen receptors and may visualize prostate cancers, and also explores how FDHT accumulation relates to androgen receptor expression in tumor samples. Participants will undergo PET scans with FDHT alone or combined with FDG at baseline, week 4, week 12, and then every 12 weeks during treatment for up to 12 months, with a maximum of 8 scan sets per year and 40 lifetime scan sets. Blood samples may be collected to study FDHT pharmacokinetics, and dynamic scans may be performed if additional pharmacokinetic data is needed. The study assesses radiotracer uptake site-by-site compared to conventional imaging like bone scans, CT, and MRI. During the study, participants will have serial PET imaging and possibly blood draws to monitor radiotracer distribution and metabolism. Researchers will measure FDHT accumulation and its correlation with other imaging and clinical markers at baseline, 4 weeks, 12 weeks, and up to 2 years for some outcomes. The main outcome is to assess FDHT uptake in progressive prostate cancer, along with secondary measures including its relationship with FDG uptake, treatment effects, tumor tissue analyses, and tumor diffusivity. The study is conducted by Memorial Sloan Kettering Cancer Center and aims to improve early assessment of treatment outcomes.
CONDITIONS
Brief Title
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer
Research Team
H
Heiko Schoder, MD
M
Michael Morris, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here